Cas9 Stable Cell Line - HEL

The HEL cell line, derived from Hodgkin''s lymphoma patients, is a widely used human erythroleukemia cell line in hematology and oncology research. By integrating the CRISPR-associated protein 9 (Cas9) gene into the HEL genome, a Cas9-stable cell line, HEL, was constructed, achieving permanent expression of the Cas9 nuclease. This modification creates a versatile cellular tool where Cas9 is continuously activated, eliminating the need for transient transfection in gene-editing experiments. The HEL cell line is particularly valuable due to its important role in the study of hematological diseases, cancer mechanisms, and hematopoietic differentiation. These cells maintain stable Cas9 expression during passage, ensuring the efficiency of large-scale genome screening or longitudinal studies.

The Cas9 Stable Cell Line - HEL holds transformative potential in biomedical research. It accelerates functional genomics research by guiding RNA delivery to achieve rapid knockout or knock-in of target genes, thus promoting research into leukemia progression, drug resistance, and gene function in signal transduction pathways. In drug development, researchers utilize this cell line for high-throughput screening, identifying therapeutic targets or validating drug efficacy by editing oncogenes/tumor suppressor genes. Furthermore, it supports disease modeling, for example, generating mutations that mimic hematologic malignancies to study pathogenesis. Beyond cancer research, it also aids in immunology (e.g., cytokine receptor editing) and regenerative medicine (e.g., hemoglobin gene regulation). This cell product simplifies the CRISPR workflow, reduces experimental variability, and improves the reproducibility of basic and translational research.